Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study

References

• Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, Rodriguez MJ, Rele R, Orta J, Kharbeng A, et al.; on behalf of the SOHO Study Group. 2003. The Clinical global impression-schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand. 107:16–23.
   Web of Science ®Google Scholar
• Rocca P, Montemagni C, Castagna F, Giugiario M, Scalese M, Bogetto F. 2009. Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 33:373–379.
   PubMed Web of Science ®Google Scholar
• Alonso J, Olivares JM, Ciudad A, Manresa J, Casado A, Gilaberte I. 2008. Development and validation of the Social Functioning Scale, short version, in schizophrenia for its use in the clinical practice. Actas Esp Psiquiatr. 36:102–110.
   PubMed Web of Science ®Google Scholar
• Ballon J, Stroup TS. 2013. Polypharmacy for schizophrenia. Curr Opin Psychiatry. 26:208–213.
   PubMed Web of Science ®Google Scholar
• Bandelow B, Meier A. 2003. Aripiprazole, a “Dopamine-serotonin system stabilizer” in the treatment of psychosis. German J Psychiatry. 6:9–16.
   Google Scholar
• Belgamwar RB, El-Sayeh HGG. 2007. Aripiprazole versus placebo for schizophrenia. In: Belgamwar RB, editor. Cochrane database of systematic reviews. Chichester (UK): Wiley.
   Google Scholar
• Byerly MJ, Nakonezny PA, Lescouflair E. 2007. Antipsychotic medication adherence in schizophrenia. Psychia Clin N Am. 30:437–452.
   PubMed Web of Science ®Google Scholar
• Christensen AF, Poulsen J, Nielsen CT, Bork B, Christensen A, Christensen M. 2006. Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study. Acta Psychiatr Scand. 113:148–153.
   PubMed Web of Science ®Google Scholar
• Correll CU, Lencz T, Malhotra AK. 2011. Antipsychotic drugs and obesity. Trends Mol Med. 17:97–107.
   PubMed Web of Science ®Google Scholar
• Cuomo A, Goracci A, Fagiolini A. 2018. Aripiprazole use during pregnancy, peripartum and lactation. A systematic literature search and review to inform clinical practice. J Affect Disord. 228:229–237.
   PubMed Web of Science ®Google Scholar
• Cutler AJ, Marcus RN, Hardy SA, O'Donnell A, Carson WH, McQuade RD. 2006. The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. CNS Spectr. 11:691–702.
   PubMed Web of Science ®Google Scholar
• de Bartolomeis A, Tomasetti C, Iasevoli F. 2015. Update on the mechanism of action of aripiprazole: translational insights into antipsychotic strategies beyond dopamine receptor antagonism. CNS Drugs. 29:773–799.
   PubMed Web of Science ®Google Scholar
• De Hert M, Hanssens L, Van Winkel R, Wampers M, Van Eyck D, Scheen A, Peuskens J. 2007. A case series: evaluation of the metabolic safety of aripiprazole. Schizophr Bull. 33:823–830.
   PubMed Web of Science ®Google Scholar
• Di Lorenzo R, Ferri P, Cameli M, Rovesti S, Piemonte C. 2019. Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting. Neuropsychiatr Dis Treat. 15:183–198.
   PubMed Web of Science ®Google Scholar
• Emsley R, Chiliza B, Asmal L. 2013. The evidence for illness progression after relapse in schizophrenia. Schizophr Res. 148:117–121.
   PubMed Web of Science ®Google Scholar
• Endicott J, Spitzer RL, Fleiss JL, Cohen J. 1976. The global assessment scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 33:766–771.
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Alfonsi E, Amodeo G, Cenci M, Di Lella M, Farinella F, Ferraiuolo F, Fraguas D, Loparco N, Gutierrez-Rojas L, et al. 2016. Switching long acting antipsychotic medications to aripiprazole long acting once-a-month: expert consensus by a panel of Italian and Spanish psychiatrists. Expert Opin Drug Saf. 15:449–455.
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Brugnoli R, Di Sciascio G, De Filippis S, Maina G. 2015. Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists. Expert Opin Pharmacother. 16:727–737.
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Sanchez R, Perry PP, Jin N, Peters-Strickland T, Johnson BR, Baker RA, Eramo A, McQuade RD, Carson WH, et al. 2014. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry. 205:135–144.
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Uchida H. 2014. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Neuropsychopharm. 17:1083–1093.
   PubMed Web of Science ®Google Scholar
• Jeong H, Lee M. 2013. Long-acting injectable antipsychotics in first-episode schizophrenia. Clin Psychopharmacol Neurosci. 11:1–6.
   PubMed Web of Science ®Google Scholar
• Kahn RS, Giannopoulou A. 2015. The safety, efficacy and tolerability of Abilify Maintena for the treatment of schizophrenia. Expert Rev Neurother. 15:969–981.
   PubMed Web of Science ®Google Scholar
• Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW. 2002. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 63:763–771.
   PubMed Web of Science ®Google Scholar
• Kane JM, Peters-Strickland T, Baker RA, Hertel P, Eramo A, Jin N, Perry PP, Gara M, McQuade RD, Carson WH, et al. 2014. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 75:1254–1260.
   PubMed Web of Science ®Google Scholar
• Kane JM, Sanchez R, Perry PP, Jin N, Johnson BR, Forbes RA, McQuade RD, Carson WH, Fleischhacker WW. 2012. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 73:617–624.
   PubMed Web of Science ®Google Scholar
• Karagianis J, Novick D, Pecenak J, Haro JM, Dossenbach M, Treuer T, Montgomery W, Walton R, Lowry AJ. 2009. Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients*. Int J Clin Pract. 63:1578–1588.
   PubMed Web of Science ®Google Scholar
• Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, Archibald D, Ingenito G, Marcus R, Pigott T. 2003. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharm. 6:325–337.
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 13:261–276.
   PubMed Web of Science ®Google Scholar
• L’Italien GJ, Casey DE, Kan HJ, Carson WH, Marcus RN. 2007. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. J Clin Psychiatry. 68:1510–1516.
   PubMed Web of Science ®Google Scholar
• Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. 2005. What does the PANSS mean? Schizophr Res. 79:231–238.
   PubMed Web of Science ®Google Scholar
• Lieberman JA. 2004. Dopamine partial agonists. CNS Drugs. 18:251–267.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, et al. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 353:1209–1223.
   PubMed Web of Science ®Google Scholar
• Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. 1987. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand. 334:1–100.
   Google Scholar
• Llorca PM, Abbar M, Courtet P, Guillaume S, Lancrenon S, Samalin L. 2013. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry. 13:340.
   PubMed Web of Science ®Google Scholar
• Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T. 2003. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 61:123–136.
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Daniel DG, Carson WHJ, McQuade RD, Marcus RN. 2007. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res. 41:895–905.
   PubMed Web of Science ®Google Scholar
• Montejo AL, Riesgo Y, Luque J, Barber I; Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. 2010. Observational, open-label, prospective multicenter study of sexual function in patients starting treatment with aripiprazole. Actas Esp Psiquiatr. 38:13–21.
   PubMed Web of Science ®Google Scholar
• Naber D, Baker RA, Eramo A, Forray C, Hansen K, Sapin C, Peters-Strickland T, Nylander AG, Hertel P, Nitschky Schmidt S, et al. 2018. Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study. Schizophr Res. 192:205–210.
   PubMed Web of Science ®Google Scholar
• Naber D, Hansen K, Forray C, Baker RA, Sapin C, Beillat M, Peters-Strickland T, Nylander A-G, Hertel P, Andersen HS, et al. 2015. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophr Res. 168:498–504.
   PubMed Web of Science ®Google Scholar
• Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG; Aripiprazole Study Group. 2003. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. 64:1048–1056.
   PubMed Web of Science ®Google Scholar
• Potkin SG, Loze J-Y, Forray C, Baker RA, Sapin C, Peters-Strickland T, Beillat M, Nylander AG, Hertel P, Nitschky Schmidt S, et al. 2016. Multidimensional assessment of functional outcomes in schizophrenia: results from QUALIFY, a head-to-head trial of aripiprazole once-monthly and paliperidone palmitate. Int J Neuropsychopharmacol. 20:40–49.
   Web of Science ®Google Scholar
• Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR. 2003. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 60:681–690.
   PubMed Web of Science ®Google Scholar
• Taylor DM, Sparshatt A, Amin F, Osborne I, Dzahini O, Hughes G, Fischetti C. 2017. Aripiprazole long-acting injection – a mirror image study of its effects on hospitalisation at one year. J Psychopharmacol. 31:1564–1569.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Mittendorfer-Rutz E, Majak M, Mehtälä J, Hoti F, Jedenius E, Enkusson D, Leval A, Sermon J, Tanskanen A, et al. 2017. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry. 74:686.
   PubMed Web of Science ®Google Scholar
• Trives MZ, Llácer JMB, Escudero MAG, Pastor CJM. 2013. Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection. J Clin Psychopharmacol. 33:538–541.
   PubMed Web of Science ®Google Scholar
• Wolfgang Fleischhacker W, Sanchez R, Johnson B, Jin N, Forbes RA, McQuade R, Baker RA, Carson W, Kane JM. 2013. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. Int Clin Psychopharmacol. 28:171–176.
   PubMed Web of Science ®Google Scholar
• World Health Organization. 1993. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. doi:10.1002/1520-6505(2000)9:5<201::AID-EVAN2>3.3.CO;2-P
   Google Scholar